<a href="https://laohu8.com/S/EDSA">Edesa Biotech</a> Inc. reports FY research and development expenses of USD 3.7 million, up 27%
Edesa Biotech Inc. reported a net loss of USD 7.2 million, or USD 1.27 per common share, for the full year ended September 30, 2025. This compares to a net loss of USD 6.2 million, or USD 1.93 per common share, for the previous year. As of September 30, 2025, Edesa Biotech Inc. held cash and cash equivalents of USD 10.8 million and reported working capital of USD 10.4 million. General and administrative expenses for the period increased to USD 4.2 million, primarily due to higher noncash share-based compensation. Total other income for the year was USD 0.7 million, mainly reflecting a decrease in interest income. Subsequent to the fiscal year end, the company raised USD 3.4 million in net proceeds from the sale of common shares under an at-the-market offering program.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edesa Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9601061) on December 12, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。